KMT2D |
MLL2 |
WM/LPL |
|
1 |
機能喪失 |
|
|
KRAS |
|
T-ALL |
|
1 |
機能獲得(変異:G12D/G13Dなど) |
|
G12, G13, Q61 |
KMT2D |
MLL2 |
T-ALL |
|
1 |
機能喪失 |
|
|
KMT2A |
MLL |
T-ALL |
|
1 |
機能獲得(融合:KMT2A::MLLT1など) |
t(11;19)(q23;p13)など |
|
KMT2D |
MLL2 |
SMZL |
|
1 |
機能喪失 |
|
|
KLF2 |
|
SMZL |
|
1 |
機能喪失 |
|
|
KRAS |
|
SM |
あり |
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KIT |
C-KIT |
SM |
あり |
1 |
機能獲得(変異:D816V, deletion of codon 419 on exon 9, A502_Y503dup in exon 9, p.F522C, p.V560Gなど) |
|
D816V |
KRAS |
|
Rosai-Dorfman Disease |
|
1 |
機能獲得 |
|
G12, G13, Q61 |
KLHL6 |
|
POEMS syndrome |
|
1 |
機能不明(変異) |
|
|
KLHL14 |
|
PCNSL |
|
1 |
機能不明(変異) |
|
|
KMT2D |
MLL2 |
PCFCL |
|
1 |
機能喪失 |
|
|
KRAS |
|
PBL |
|
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KMT2D |
MLL2 |
NMZL |
|
1 |
機能喪失 |
|
|
KLF2 |
|
NMZL |
|
1 |
機能喪失 |
|
|
KMT2A |
MLL |
MPAL with t(v;11q23.3); KMT2A rearranged |
|
1 |
機能獲得(融合) |
t(v;11q23.3) |
|
KRAS |
|
MM |
|
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KMT2C |
MLL3 |
MM |
|
2 |
機能喪失 |
|
|
KMT2B |
|
MM |
|
2 |
機能喪失 |
|
|
KLHL6 |
|
MM |
|
2 |
機能不明(変異) |
|
|
KDM6A |
|
MM |
|
2 |
機能喪失 |
|
|
KDM5C |
|
MM |
|
2 |
機能喪失 |
|
|
KRAS |
|
MDS |
あり |
1 |
機能獲得(変異:G12D/S/A/V, Q61Pなど) |
|
G12, G13, Q61 |
KMT2A |
MLL |
MDS |
|
1 |
機能獲得(変異:PTD) |
|
|
KMT2D |
MLL2 |
MCL |
|
1 |
機能喪失 |
|
|
KRAS |
|
Langerhans cell sarcoma |
|
1 |
機能喪失(変異) |
|
G12, G13, Q61 |
KRAS |
|
Langerhans cell histiocytosis |
|
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KRAS |
|
JMML associated with neurofibromatosis, Noonan syndrome or Noonan syndrome-like disorders |
あり |
1 |
機能獲得(変異:G12D/S/A/V, Q61Pなど) |
|
G12, G13, Q61 |
KMT2D |
MLL2 |
iNKLPD |
|
1 |
機能喪失 |
|
|
KRAS |
|
Indeterminate dendritic cell tumor |
|
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KRAS |
|
IDCS |
|
1 |
機能獲得 (変異) |
|
G12, G13, Q61 |
KRAS |
|
Histiocytic sarcoma |
|
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KMT2D |
|
Histiocytic sarcoma |
|
1 |
機能獲得(変異) |
|
|
KMT2D |
|
HGBL |
|
|
|
|
|
KMT2C |
MLL3 |
HCL-v (SBLPN) |
|
1 |
機能喪失 |
|
|
KMT2C |
MLL3 |
HCL |
|
1 |
機能喪失 |
|
|
KLF2 |
|
HCL |
|
1 |
機能喪失 |
|
|
KMT2D |
MLL2 |
FL |
|
1 |
機能喪失 |
|
|
KMT2C |
MLL3 |
FL |
|
1 |
機能喪失 |
|
|
KRAS |
|
ETP-ALL |
|
1 |
機能獲得(変異:G12D/G13Dなど) |
|
G12, G13, Q61 |
KMT2E |
|
ETP-ALL |
|
2 |
機能獲得(融合:KMT2E::ASNS) |
|
|
KRAS |
|
Erdheim-Chester disease |
|
1 |
機能獲得 (変異) |
|
G12, G13, Q61 |
KMT2D |
MLL2 |
ENKTL |
|
1 |
機能喪失 |
|
|
KIT |
C-KIT |
ENKTL |
|
1 |
機能獲得(変異) |
|
D816V |
KMT2D |
MLL2 |
EATL |
|
1 |
機能喪失 |
|
|
KMT2D |
MLL2 |
DLBCL |
|
1 |
機能喪失 |
|
|
KMT2C |
MLL3 |
DLBCL |
|
1 |
機能喪失 |
|
|
KRAS |
|
Disseminated juvenile xanthogranuloma |
あり |
1 |
機能獲得 (変異) |
|
G12, G13, Q61 |
KDM6A |
UTX |
CMML |
|
2 |
機能喪失 |
|
|
KRAS |
|
CHIP |
|
2 |
機能獲得(変異) |
|
G12, G13, Q61 |
KMT2D |
MLL2 |
C-ALCL |
|
1 |
機能喪失 |
|
|
KMT2A |
MLL |
C-ALCL |
|
1 |
機能不明(変異) |
|
|
KMT2D |
MLL2 |
Breast implant-associated ALCL |
|
1 |
機能喪失 |
|
|
KMT2C |
MLL3 |
Breast implant-associated ALCL |
|
1 |
機能喪失 |
|
|
KRAS |
|
BPDCN |
あり |
1 |
機能獲得 |
|
G12, G13, Q61 |
KMT2D |
|
BPDCN |
|
2 |
|
|
|
KIT |
C-KIT |
BPDCN |
|
1 |
機能獲得 |
|
D816V |
KDM5C |
|
BPDCN |
|
2 |
機能喪失 |
|
|
KMT2A |
MLL |
B-ALL/LBLL with t(v;11q23.3); KMT2A rearranged |
|
1 |
機能獲得(融合:KMT2A::AFF1など) |
t(4;11)(q21;q23), t(9;11)(p21;q23), t(11;19)(q23;p13)など |
|
KRAS |
|
B-ALL/LBLL |
|
1 |
機能獲得(変異:G12D/G13Dなど) |
|
G12, G13, Q61 |
KDM6A |
UTX |
B-ALL/LBLL |
|
2 |
機能喪失 |
|
|
KMT2D |
MLL2 |
ANKL |
|
1 |
機能喪失 |
|
|
KMT2A |
MLL |
AML with t(9;11)(p21.3;q23.3); MLLT3::KMT2A |
|
1 |
機能獲得(融合:KMT2A::MLLT3, KMT2A::MLLT4, KMT2A::AFF1, など) |
t(9;11)(p21;q23)など |
|
KMT2A |
|
AML with MRC |
|
2 |
機能獲得(融合:KMT2A::CREBBPなど) |
t(11;16)(q23.3;p13.3), t(2;11)(p21;q23.3) |
|
KAT6A |
|
AML with MRC |
|
1 |
機能獲得(融合:KAT6A::CREBBP) |
t(8;16)(p11;p13) |
|
KRAS |
|
AML |
あり |
1 |
機能獲得(変異:G12D/S/A/V, Q61Pなど) |
|
G12, G13, Q61 |
KMT2A |
MLL |
AML |
|
1 |
機能獲得(変異:PTD) |
|
|
KMD5A |
|
AML |
|
1 |
機能獲得(融合:NUP98::KDM5A) |
t(11;12)(p15;p13) |
|
KIT |
C-KIT |
AML |
|
1 |
機能獲得(変異:D816Vなど) |
|
D816V |
KANSL1 |
|
Myeloid leukaemia associated with Down syndrome |
|
2 |
機能喪失 |
|
|
KRAS |
|
MPDMN |
あり |
1 |
機能獲得(変異) |
|
G12, G13, Q61 |
KMT2A |
MLL |
Indeterminate dendritic cell tumor |
|
1 |
機能獲得(変異) |
|
|